Literature DB >> 571291

An analysis for transient states with application to tumor shrinkage.

N R Temkin.   

Abstract

The evaluation of therapies for chronic diseases is often based on the frequency and/or the duration of improvement. Treated separately, these endpoints may give contradictory impressions of the efficacy of the therapy. We propose a more unified method of summarizing improvement-related data--the probability of being in response, i.e., improved, as a function of time. Although improvement is not the only endpoint considered in most trials and this function will not always provide a clear answer to the question of which treatment has better improvement-related characteristics, it does combine the information on several endpoints usually considered separately into a single easily interpreted item. This function is estimated using the method of maximum likelihood on a distribution-free stochastic model of times to improvement and failure. Censored observations are taken into account. A detailed example using data from a cancer clinical trial is presented.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 571291

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

1.  Asymptotic theory for the Cox semi-Markov illness-death model.

Authors:  Youyi Shu; John P Klein; Mei-Jie Zhang
Journal:  Lifetime Data Anal       Date:  2007-03       Impact factor: 1.588

2.  Estimation of prolongation of hospital stay attributable to nosocomial infections: new approaches based on multistate models.

Authors:  G Schulgen; M Schumacher
Journal:  Lifetime Data Anal       Date:  1996       Impact factor: 1.588

3.  Nonparametric tests for multistate processes with clustered data.

Authors:  Giorgos Bakoyannis; Dipankar Bandyopadhyay
Journal:  Ann Inst Stat Math       Date:  2022-01-22       Impact factor: 1.180

4.  Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

Authors:  Sally Anne Garnett; Miguel Martin; Guy Jerusalem; Lubos Petruzelka; Roberto Torres; Igor N Bondarenko; Rustem Khasanov; Didier Verhoeven; José L Pedrini; Iva Smirnova; Mikhail R Lichinitser; Kelly Pendergrass; Justin P O Lindemann; Angelo Di Leo
Journal:  Breast Cancer Res Treat       Date:  2013-02-03       Impact factor: 4.872

5.  The Seattle evaluation of computerized drug profiles: effects on prescribing practices and resource use.

Authors:  T D Koepsell; A L Gurtel; P H Diehr; N R Temkin; K H Helfand; M A Gleser; R K Tompkins
Journal:  Am J Public Health       Date:  1983-08       Impact factor: 9.308

6.  A multistate model for events defined by prolonged observation.

Authors:  Vernon T Farewell; Li Su
Journal:  Biostatistics       Date:  2010-06-25       Impact factor: 5.899

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.